ArticlePLoS neglected tropical diseases2025
Continuous detection of Chikungunya Virus in a passive surveillance system in southern Thailand, 2012-2019.
Article in PLoS neglected tropical diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Expert Recommendations to Strengthen Chikungunya Outbreak Surveillance and Reporting for Traveler Health Protection.The American journal of tropical medicine and hygiene · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chikungunya virus (CHIKV) infections are distributed across the globe, causing significant and, often, lasting morbidity. CHIKV vaccines are in development, but their evaluation is limited by the unpredictability of CHIKV transmission, which classically manifests as explosive epidemics separated by variable interepidemic periods. A passive surveillance study for undifferentiated febrile illness was established in southern Thailand in 2012 and is ongoing. Among 1466 febrile individuals with acute and convalescent specimens, 398 (27.1%) had molecular or serological evidence of acute CHIKV infection. The proportions of participants confirmed to have CHIKV infection differed by year, being highest during epidemic periods (41.1% in 2018-2019, corresponding to a large regional CHIKV outbreak, compared to 19.3% in 2012-2017). These data suggest persistent circulation of CHIKV in the study area, though additional studies are needed to confirm these findings and to discern whether this persistence reflects widespread, low-level transmission or migrating bursts of focal epidemic activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.